Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma

被引：13

作者：

Martin, Thomas G. ^{[1
]}

Madduri, Deepu ^{[2
]}

Pacaud, Lida ^{[3
]}

Usmani, Saad Z. ^{[4
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA

[2] Janssen Res & Dev, Raritan, NJ 08869 USA

[3] Legend Biotech USA Inc, Somerset, NJ 08873 USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

来源：

FUTURE ONCOLOGY | 2023年 / 19卷 / 34期

关键词：

B-cell maturation antigen; CAR-T therapy; chimeric antigen receptor; ciltacabtagene autoleucel; efficacy; multiple myeloma; relapsed; refractory; safety; CILTACABTAGENE AUTOLEUCEL;

D O I：

10.2217/fon-2022-1317

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received & GE;4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Approval in the EU followed for patients with & GE;3 prior therapies. At median 28-month follow-up, the pivotal CARTITUDE-1 trial showed a 98% response rate (83% stringent complete response); median progression-free survival had not been reached, and adverse events could be managed with supportive therapy. Cilta-cel efficacy and safety in earlier lines of therapy, and its optimal sequencing in a complex treatment landscape are important areas of investigation.

引用

页码：2297 / 2311

页数：15

共 50 条

[1] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. [J].

Anderson, Larry D., Jr. ;

Munshi, Nikhil C. ;

Shah, Nina ;

Jagannath, Sundar ;

Berdeja, Jesus G. ;

Lonial, Sagar ;

Raje, Noopur S. ;

Siegel, David Samuel DiCapua ;

Lin, Yi ;

Oriol, Albert ;

Moreau, Philippe ;

Yakoub-Agha, Ibrahim ;

Delforge, Michel ;

Petrocca, Fabio ;

Patel, Payal ;

Huang, Liping ;

Campbell, Timothy B. ;

Hege, Kristen ;

San-Miguel, Jesus F. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[2]

[Anonymous], 2022, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), B-cell Lymphomas, Version 5

[3] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].

Berdeja, Jesus G. ;

Madduri, Deepu ;

Usmani, Saad Z. ;

Jakubowiak, Andrzej ;

Agha, Mounzer ;

Cohen, Adam D. ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Htut, Myo ;

Lesokhin, Alexander ;

Deol, Abhinav ;

Munshi, Nikhil C. ;

O'Donnell, Elizabeth ;

Avigan, David ;

Singh, Indrajeet ;

Zudaire, Enrique ;

Yeh, Tzu-Min ;

Allred, Alicia J. ;

Olyslager, Yunsi ;

Banerjee, Arnob ;

Jackson, Carolyn C. ;

Goldberg, Jenna D. ;

Schecter, Jordan M. ;

Deraedt, William ;

Zhuang, Sen Hong ;

Infante, Jeffrey ;

Geng, Dong ;

Wu, Xiaoling ;

Carrasco-Alfonso, Marlene J. ;

Akram, Muhammad ;

Hossain, Farah ;

Rizvi, Syed ;

Fan, Frank ;

Lin, Yi ;

Martin, Thomas ;

Jagannath, Sundar .

LANCET, 2021, 398 (10297) :314-324

[4]

Bristol-Myers Squibb Pharma, ABECMA ID VICL SUMM

[5]

Celgene Corporation a Bristol-Myers Squibb Company, ABECMA ID VICL PRESC

[6] Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma [J].

Chari, Ajai ;

Vogl, Dan T. ;

Gavriatopoulou, Maria ;

Nooka, Ajay K. ;

Yee, Andrew J. ;

Huff, Carol A. ;

Moreau, Philippe ;

Dingli, David ;

Cole, Craig ;

Lonial, Sagar ;

Dimopoulos, Meletios ;

Stewart, A. Keith ;

Richter, Joshua ;

Vij, Ravi ;

Tuchman, Sascha ;

Raab, Marc S. ;

Weisel, Katja C. ;

Delforge, Michel ;

Cornell, Robert F. ;

Kaminetzky, David ;

Hoffman, James E. ;

Costa, Luciano J. ;

Parker, Terri L. ;

Levy, Moshe ;

Schreder, Martin ;

Meuleman, Nathalie ;

Frenzel, Laurent ;

Mohty, Mohamad ;

Choquet, Sylvain ;

Schiller, Gary ;

Comenzo, Raymond L. ;

Engelhardt, Monika ;

Illmer, Thomas ;

Vlummens, Philip ;

Doyen, Chantal ;

Facon, Thierry ;

Karlin, Lionel ;

Perrot, Aurore ;

Podar, Klaus ;

Kauffman, Michael G. ;

Shacham, Sharon ;

Li, Lingling ;

Tang, Shijie ;

Picklesimer, Carla ;

Saint-Martin, Jean-Richard ;

Crochiere, Marsha ;

Chang, Hua ;

Parekh, Samir ;

Landesman, Yosef ;

Shah, Jatin .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (08) :727-738

[7] Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy [J].

Cho, Shih-Feng ;

Anderson, Kenneth C. ;

Tai, Yu-Tzu .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[8] Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents [J].

Cohen, Adam D. ;

Mateos, Maria-Victoria ;

Cohen, Yael C. ;

Rodriguez-Otero, Paula ;

Paiva, Bruno ;

van de Donk, Niels W. C. J. ;

Martin, Thomas ;

Suvannasankha, Attaya ;

De Braganca, Kevin C. ;

Corsale, Christina ;

Schecter, Jordan M. ;

Varsos, Helen ;

Deraedt, William ;

Wang, Liwei ;

Vogel, Martin ;

Roccia, Tito ;

Xu, Xiaoying ;

Mistry, Pankaj ;

Zudaire, Enrique ;

Akram, Muhammad ;

Nesheiwat, Tonia ;

Pacaud, Lida ;

Avivi, Irit ;

San-Miguel, Jesus .

BLOOD, 2023, 141 (03) :219-230

[9] Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies [J].

Cohen, Adam D. ;

Parekh, Samir ;

Santomasso, Bianca D. ;

Gallego Perez-Larraya, Jaime ;

van de Donk, Niels W. C. J. ;

Arnulf, Bertrand ;

Mateos, Maria-Victoria ;

Lendvai, Nikoletta ;

Jackson, Carolyn C. ;

De Braganca, Kevin C. ;

Schecter, Jordan M. ;

Marquez, Loreta ;

Lee, Erin ;

Cornax, Ingrid ;

Zudaire, Enrique ;

Li, Claire ;

Olyslager, Yunsi ;

Madduri, Deepu ;

Varsos, Helen ;

Pacaud, Lida ;

Akram, Muhammad ;

Geng, Dong ;

Jakubowiak, Andrzej ;

Einsele, Hermann ;

Jagannath, Sundar .

BLOOD CANCER JOURNAL, 2022, 12 (02)

[10] Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma [J].

Costa, Luciano J. ;

Lin, Yi ;

Cornell, R. Frank ;

Martin, Thomas ;

Chhabra, Saurabh ;

Usmani, Saad Z. ;

Jagannath, Sundar ;

Callander, Natalie S. ;

Berdeja, Jesus G. ;

Kang, Yubin ;

Vij, Ravi ;

Godby, Kelly N. ;

Malek, Ehsan ;

Neppalli, Amarendra ;

Liedtke, Michaela ;

Fiala, Mark ;

Tian, Hong ;

Valluri, Satish ;

Marino, Jennifer ;

Jackson, Carolyn C. ;

Banerjee, Arnob ;

Kansagra, Ankit ;

Schecter, Jordan M. ;

Kumar, Shaji ;

Hari, Parameswaran .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05) :326-335

← 1 2 3 4 5 →